<DOC>
	<DOCNO>NCT01617005</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy tocilizumab participant active moderate severe RA inadequate response non-biologic DMARDs . Data collect eligible participant initiate tocilizumab treatment 6 month .</brief_summary>
	<brief_title>A Study Tocilizumab Participants With Active Rheumatoid Arthritis ( RA ) Inadequate Response Non-Biological Disease-modifying Anti-rheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Moderate severe active RA ( European League Against Rheumatism [ EULAR ] criterion ) Inadequate response DMARDs tumor necrosis factor ( TNF ) antagonists Initiating treatment tocilizumab accord SPC Rheumatic autoimmune disease RA Prior history current inflammatory joint disease RA Previous treatment biological drug use treatment RA Previous treatment tocilizumab Any contraindication treatment tocilizumab Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow enrollment Pregnant woman nurse ( breastfeed ) mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>